IL2 and ovarian neoplasm: NK cell infusion reduced the growth of ovarian tumors (no treatment vs NK + PBS, * p < 0.05), and the addition of rhIL-2 injection to facilitate NK efficacy led to more significant inhibition of tumor growth (no treatment vs NK + IL-2, *** p < 0.001).